



NEWS

FOR IMMEDIATE RELEASE

ONCOMETHYLOME SCIENCES ANNOUNCES AGREEMENT WITH SEROLOGICALS CORPORATION FOR METHYLATION TECHNOLOGIES

LIEGE, BELGIUM and DURHAM, N.C. USA – October 7, 2003 – OncoMethylome Sciences S.A. announced today that it has entered into an agreement with Serologicals Corporation (NASDAQ: SERO) for its methylation technologies. By this agreement, existing sublicenses were restructured whereby OncoMethylome Sciences obtained the rights to the clinical development market in addition to its ongoing in-vitro diagnostics business, whereas Serologicals Corporation was granted a sublicense for existing products and an option to future methylation products for the scientific research market.

OncoMethylome Sciences, which already has several early cancer detection products in its pipeline, thereby reinforces its position in the genetic cancer diagnostics market for which it controls the rights for the development, commercialization, and manufacturing of products and services based on methylation specific amplification (MSP) technologies. Serologicals Corporation, with its research product division Chemicon International, Inc., is a global leader in marketing and sales of methylation technologies to the research market. OncoMethylome Sciences will receive a royalty fee on all current and future sales by Serologicals Corporation for this market segment.

The agreement affords both companies the opportunity to focus on products and services in markets in which each holds a competitive advantage. Research has demonstrated that certain genes' methylation patterns change during the development and progression of cancer. OncoMethylome Sciences' MSP is a unique and patented technology for accurate and sensitive determination of the methylation state of genomic DNA from various sources, including cells in culture, tumor tissue and other body fluids.

Herman Spolders, Chief Executive Officer of OncoMethylome Sciences S.A. stated: "We are very pleased to have this relationship with Serologicals for serving the scientific research market. Our new technologies and products will now be introduced to researchers in the earliest possible stage. This relationship is an important step to establish us as a leading company for Methylation Technologies."

OncoMethylome Sciences announces agreement with Serologicals

“Our agreement with OncoMethylome Sciences strengthens our commitment to provide the cancer research community with the finest products enabling advances in the study of gene methylation patterns,” said David A. Dodd, President & Chief Executive Officer of Serologicals. “This collaboration lays the foundation for a strong, ongoing and mutually rewarding relationship providing cancer researchers and other scientists with the innovative research tools and technologies needed to make breakthrough discoveries.”

In recent years, numerous researchers and clinical trials have shown that the methylation of genes is a promising process for identifying numerous types of cancers at an early stage of the development of the disease. In numerous publications of peer-reviewed journals and at recent conferences, such as ASCO and AACR, increasingly strong data has been presented about the clinical applications of methylation technologies in the cancer field.

About OncoMethylome Sciences S.A.

OMS is a leader in the field of gene methylation tests that (1) detect cancer at a much earlier stage of the disease and at a higher level of accuracy than currently available tests and (2) predict and monitor response to cancer therapy for optimal and more individualized treatment decisions.

OMS has licensed a strong patent portfolio that includes specific methylated gene markers and MSP (Methylation Specific PCR) technology. The company has collaborations with leading international molecular oncology scientists including Stephen Baylin MD, James Herman MD and David Sidransky MD from Johns Hopkins University (Baltimore, Maryland, USA).

The OncoMethylome Sciences laboratory and headquarters are in Liège, Belgium and its USA offices are in Durham, NC, near Research Triangle Park. For more information, visit the website of the Company at www.oncomethylome.com or:

In Europe, contact Drs. Herman Spolders, CEO,
Tel. +32-478-541-330
Herman.Spolders@oncomethylome.com

In North America, contact Harry Schrickx, VP Business Development
Tel. +1-919-949-3606
Harry.Schrickx@oncomethylome.com

Serologicals is a registered trademark of Serologicals Royalty Company.
OncoMethylome Sciences is a registered trademark of OncoMethylome Sciences S.A.